CY1117838T1 - Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου - Google Patents

Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου

Info

Publication number
CY1117838T1
CY1117838T1 CY20161100736T CY161100736T CY1117838T1 CY 1117838 T1 CY1117838 T1 CY 1117838T1 CY 20161100736 T CY20161100736 T CY 20161100736T CY 161100736 T CY161100736 T CY 161100736T CY 1117838 T1 CY1117838 T1 CY 1117838T1
Authority
CY
Cyprus
Prior art keywords
cancer treatment
prediction factors
cancer
treatment
methods
Prior art date
Application number
CY20161100736T
Other languages
English (en)
Inventor
Deborah Ricci
Weimin Li
Erin Devay Henitz
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1117838T1 publication Critical patent/CY1117838T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους πρόβλεψης απόκρισης σε μία θεραπευτική αγωγή καρκίνου για προσδιορισμό επιπέδου της CD68 ή PSMB1(PI 1Α) πολυμορφισμού σε ένα βιολογικό δείγμα και της παρουσίας ή ποσότητας ενός δεύτερου βιοδείκτη στον ασθενή. Η εφεύρεση παρέχει επίσης κιτ και μεθόδους για θεραπευτική αγωγή καρκίνου.
CY20161100736T 2011-08-11 2016-07-26 Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου CY1117838T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522596P 2011-08-11 2011-08-11
US201161560555P 2011-11-16 2011-11-16
PCT/US2012/049941 WO2013022935A1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment

Publications (1)

Publication Number Publication Date
CY1117838T1 true CY1117838T1 (el) 2017-05-17

Family

ID=47668910

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100736T CY1117838T1 (el) 2011-08-11 2016-07-26 Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου

Country Status (20)

Country Link
US (1) US9322066B2 (el)
EP (1) EP2742356B1 (el)
JP (1) JP6002222B2 (el)
CN (1) CN103930785B (el)
AU (1) AU2012294493B2 (el)
CA (1) CA2844825A1 (el)
CY (1) CY1117838T1 (el)
DK (1) DK2742356T3 (el)
ES (1) ES2586328T3 (el)
HK (2) HK1199094A1 (el)
HR (1) HRP20160851T1 (el)
HU (1) HUE029295T2 (el)
MX (1) MX357429B (el)
PL (1) PL2742356T3 (el)
PT (1) PT2742356E (el)
RS (1) RS55053B1 (el)
RU (1) RU2600026C2 (el)
SI (1) SI2742356T1 (el)
SM (1) SMT201600235B (el)
WO (1) WO2013022935A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130346093A1 (en) * 2012-06-22 2013-12-26 Quintiles Transnational Corporation Systems and Methods for Analytics on Viable Patient Populations
US10795879B2 (en) 2012-06-22 2020-10-06 Iqvia Inc. Methods and systems for predictive clinical planning and design
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
EP3191726A4 (en) * 2014-09-10 2018-12-19 Litens Automotive Partnership Proportionally damped power transfer device using torsion spring force
JP2019519548A (ja) * 2016-06-17 2019-07-11 ヴァリアン メディカル システムズ インコーポレイテッド 放射線処置と組み合わせた免疫調節剤
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
WO2018176147A1 (en) 2017-03-28 2018-10-04 Litens Automotive Partnership Isolation device with selected angle between spring stop and damping member
EP3705584A1 (en) 2019-03-05 2020-09-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
AU2002243646B2 (en) 2001-01-25 2006-06-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
CA2508348C (en) * 2002-12-06 2016-07-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
CN100366636C (zh) * 2004-12-08 2008-02-06 中国农业科学院畜牧研究所 猪生产及免疫性状相关蛋白，它的编码基因与应用
KR100653990B1 (ko) 2004-12-29 2006-12-05 주식회사 하이닉스반도체 포토마스크 데이터베이스 패턴의 불량 검사 방법
WO2006133420A2 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
AU2007284724B2 (en) 2006-08-10 2014-03-13 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
WO2009148528A2 (en) 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment

Also Published As

Publication number Publication date
EP2742356B1 (en) 2016-04-27
SMT201600235B (it) 2016-08-31
RU2600026C2 (ru) 2016-10-20
HK1199097A1 (zh) 2015-06-19
MX2014001619A (es) 2014-11-10
RS55053B1 (sr) 2016-12-30
US9322066B2 (en) 2016-04-26
EP2742356A1 (en) 2014-06-18
SI2742356T1 (sl) 2016-06-30
WO2013022935A1 (en) 2013-02-14
HUE029295T2 (en) 2017-02-28
PL2742356T3 (pl) 2016-11-30
JP6002222B2 (ja) 2016-10-05
AU2012294493B2 (en) 2017-02-23
DK2742356T3 (en) 2016-05-23
CN103930785B (zh) 2016-05-18
CA2844825A1 (en) 2013-02-14
CN103930785A (zh) 2014-07-16
HK1199094A1 (en) 2015-06-19
MX357429B (es) 2018-07-09
PT2742356E (pt) 2016-06-06
RU2014108986A (ru) 2015-09-20
US20130216524A1 (en) 2013-08-22
ES2586328T3 (es) 2016-10-13
JP2014524571A (ja) 2014-09-22
AU2012294493A1 (en) 2014-02-20
HRP20160851T1 (hr) 2016-09-23

Similar Documents

Publication Publication Date Title
CY1117838T1 (el) Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
CY1119262T1 (el) Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
EA201490999A1 (ru) Способ проведения количественных анализов
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201490328A1 (ru) Исследования для мониторинга нарушений свертываемости крови
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
MX2019006098A (es) Ensayo de anticuerpos.
NZ729773A (en) Biomarkers for disease progression in melanoma
BR112018008799A2 (pt) método de prognóstico
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
MX2016012278A (es) Deteccion temprana de preeclampsia.